pharmaceuticals

payoff

Teva Proves Its Decade-Hold Status With Massive Funding

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) may have just proved how financially fit and capable the company is. On Friday afternoon the global generic drug giant reported that it has ...
Read Full Story »
Prescription drugs

Are Teva Earnings Enough?

Teva Pharmaceutical Industries Limited (NYSE: TEVA) reported its second-quarter financial results Thursday before the markets opened. The company had $1.43 in earnings per share (EPS) on $5.0 billion in revenue ...
Read Full Story »
biotech

Should Gilead Really Be Rated Underperform?

Most analysts seem to be behind the growth that Gilead Sciences Inc. (NASDAQ: GILD) has seen, namely in its Hepatitis C vaccines (HCV) Harvoni and Solvaldi. For the most part ...
Read Full Story »
E000249

Who Really Won in the PDL and Ariad Royalty Deal?

The solid performance of the healthcare sector over the past year has been enhanced by mergers and acquisitions, licensing, and other forms of deals in the sector. This most recent ...
Read Full Story »
coins

Dermira Files For Secondary Offering

Dermira, Inc. (NASDAQ: DERM) filed an S-1 form with the Securities and Exchange Commission (SEC) for a secondary offering. There were no terms given in this initial filing but the ...
Read Full Story »
biotech

NantKwest Enters the Market With a Bang

NantKwest (NASDAQ: NK) entered the market Tuesday with its initial public offering (IPO). The stock priced early Tuesday morning at $25 per share coming over the top of the expected ...
Read Full Story »
pills

Are Merck Earnings Enough?

Merck & Co. Inc. (NYSE: MRK) reported its second-quarter financial results Tuesday before the markets opened. The pharmaceutical giant had $0.86 in earnings per share (EPS) on $9.8 billion in ...
Read Full Story »
Pills

Pfizer Overcomes Currency Exchange Issue with Stronger Sales of Cancer Drugs

Pfizer Inc. (NYSE: PFE) reported second quarter 2015 results before markets opened Tuesday morning. The company reported quarterly adjusted diluted earnings per share (EPS) of $0.56 and revenues of $11.9 ...
Read Full Story »
biotech

Can Nymox Sustain This Massive Rally?

Nymox Pharmaceutical Corp. (NASDAQ: NYMX) was one of the best performers on Monday despite a down day in the market. And Nymox is absolutely dominating in 2015 in terms of its ...
Read Full Story »
Pfizer logo

What to Look For in Pfizer Earnings

Before the market opens on Tuesday morning, Pfizer Inc. (NYSE: PFE) is scheduled to report second-quarter results. The company is expected to post earnings per share (EPS) of $0.52 on ...
Read Full Story »
Pills

What to Expect from Merck Earnings

Merck & Co. Inc. (NYSE: MRK) reports on Tuesday morning comes into earnings with shares up only 2.7% or so year to date, and up only about 1.7% from a ...
Read Full Story »
Biotechnology word cloud

Have Analysts Fully Priced in Praluent to Regeneron?

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (NYSE: SNY) announced last Friday that the U.S. Food and Drug Administration (FDA) approved Praluent (alirocumab) Injection. Praluent is indicated as an adjunct ...
Read Full Story »
biotech

Aimmune Prepares For IPO By Setting Expected Price Range

Aimmune Therapeutics, Inc. filed an S-1 form with the Securities and Exchange Commission (SEC) for its initial public offering. The expected price range was set as $14 to $16 for ...
Read Full Story »
Prescription drugs

Short Sellers Run For Cover From Major Pharma

The short interest data have been released for the July 15 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
biotech

BioPharma Earnings Bracing for Merck, Pfizer, Amgen, Gilead

Pharmaceutical and Biotech investors are about to get a real show for earnings this week. Big Pharma will bring earnings from Dow Jones Industrial Average companies Merck & Co. Inc. ...
Read Full Story »